Third quarter total revenue of $55.3 million , which includes TAVALISSE ® net product sales of $26.3 million , REZLIDHIA ® net product sales of $5.
5 million and GAVRETO ® net product sales of $7.1 million Entered into an agreement with Kissei to develop and commercialize REZLIDHIA in all potential indications in Japan , the Republic of Korea and Taiwan , recording an upfront cash payment of $10.0 million during the third quarter Initial data from the ongoing Phase 1b study evaluating R289, a dual IRAK1/4 inhibitor, in LR-MDS to be presented at the 66 th ASH Annual Meeting Conference call and webcast scheduled today at 4:30 p.
m. Eastern Time SOUTH SAN FRANCISCO, Calif. , Nov.
7, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the third quarter ended September 30, 2024 , including sales of TAVALISSE ® (fostamatinib disodium hexahydrate) for the treatment of chronic immune thrombocytopenia (ITP); REZLIDHIA ® (olutasidenib) for the treatment of relapsed or refractory (R/R) mutated isocitrate dehydrogenase-1 (m IDH1 ) acute myeloid leukemia (AML); and GAVRETO ® (pralsetinib) for the treatment of metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) and advanced or metastatic thyroid cancer, and recent business progress. "2024 has been a significant year for Rigel, marked by the acquisition of.